Beyond Biotech - the podcast from Labiotech
Labiotech
Najnowszy odcinek
223 odcinków
- Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.
Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer.
Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies.
01:36 – Meet Devyn Smith
07:48 – Arbor's toolbox approach versus single-editor CRISPR companies
12:16 – What PH1 is and how ABO-101 works
15:19 – Inside the Chiesi partnership for ABO-101
20:14 – Why ALS anchors Arbor's CNS pipeline
26:48 – Arbor's three-year outlook and long-term vision
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
What’s on the horizon for gene editing-based therapies?
CRISPR technology’s next wave: Ten companies to watch in 2025
Beyond CRISPR: What CAST could bring to genome editing - Partnering season is here. As the biopharma community heads to BIO-Europe and the busy end-of-year conference calendar, the question isn’t just who you meet, but how you make those meetings count. In this special episode of Beyond Biotech, we’re talking about the small details that make a big difference at global conferences.
Joining me is Shashi Koduru, Senior Director of Business Development at Vector BioMed. Shashi shares how he plans his on-site schedule, finds the right partners, and makes short meetings productive. We also talk about follow-up, sharing materials after the event, and turning a first conversation into a lasting partnership.
01:15 Meet Shashi Koduru
05:13 Vector BioMed’s mission for affordable lentiviral vectors
09:36 Cutting through the noise with early conference prep
19:04 Making the most of a 30-minute partnering meeting
22:46 How a chance BIO encounter became a client
25:24 Following up and maintaining momentum after the event
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Episode 188: How to optimize your biotech company for partnering, licensing, and business success
The ABC of biotech partnerships
Nine tips to succeed in pharma-biotech partnerships - Welcome to a special three-part series called 'The Metabolic Moment'.
In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
In part three of our series and ahead of Diabetes Awareness Month, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes, the realities of making gene therapies at scale, and where a potential one-time treatment could fit alongside GLP-1s.
02:21 Meet Ryan Confer and Genprex
09:49 What gene therapy can offer patients that GLP-1s cannot
12:36 How GPX-002 works and the type 2 diabetes data presented at ASGCT
17:22 Working with a CDMO to manufacture an AAV gene therapy at scale
20:07 Standing out from GLP-1s and stem cell approaches in diabetes
27:59 Diabetes Awareness Month and the prospect of a functional cure
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The Metabolic Moment: 3 big bets to watch in metabolic disease
Beyond GLP-1s: is there a new wave of metabolic disease treatments?
The future of diabetes treatment: Is a cure possible? - Welcome to a special three-part series called 'The Metabolic Moment'.
In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants.
02:24 Meet Paul Little
05:08 What GLP-1s leave unsolved, from muscle loss to weight rebound
10:29 How ATR-258 tunes beta-2 signalling to mimic exercise
16:11 Avoiding the cardiovascular side effects of older beta-2 agonists
19:03 What the new muscle power and body composition data mean
22:03 Phase 2 options, oral advantages and the path to partnering
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The Metabolic Moment: 3 big bets to watch in metabolic disease
Beyond Ozempic: the GLP-1 landscape in 2026
What can GLP-1s do beside treat diabetes and obesity? - Welcome to a special three-part series called 'The Metabolic Moment'.
In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
In part one of our series, I’m joined by Valeriia Simanovskaia, founder and CEO of BioBrokers, an independent capital markets and strategic advisory firm for life sciences. Trained at Harvard Medical School and based in Paris, Valeriia tracks where the money in biotech is flowing.
02:15 Meet Valeriia and BioBrokers
09:07 Discontinuation rates and what they mean for GLP-1 sales
12:39 Generic semaglutide arrives in India and Canada
16:28 Why oral GLP-1s may become a separate market segment
22:15 Amgen’s MariTide and the case for monthly dosing
32:00 Why weight maintenance is the next competitive frontier
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
The Metabolic Moment: 3 big bets to watch in metabolic disease
Beyond Ozempic: the GLP-1 landscape in 2026
Nine biotech companies that could revolutionize obesity treatments
Więcej Wiadomości podcastów
Trendy w podcaście Wiadomości
O Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Strona internetowa podcastuSłuchaj Beyond Biotech - the podcast from Labiotech, Gość Radia ZET i wielu innych podcastów z całego świata dzięki aplikacji radio.pl

Uzyskaj bezpłatną aplikację radio.pl
- Stacje i podcasty do zakładek
- Strumieniuj przez Wi-Fi lub Bluetooth
- Obsługuje Carplay & Android Auto
- Jeszcze więcej funkcjonalności









































